M&A Deal Summary |
|
|---|---|
| Date | 2011-02-07 |
| Target | Ferrosan A/S |
| Sector | Consumer Products |
| Buyer(s) | Pfizer |
| Sellers(s) | Altor Equity Partners |
| Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1849 |
| Sector | Life Science |
| Employees | 8,300 |
| Revenue | 58.5B USD (2023) |
Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.
| DEAL STATS | # |
|---|---|
| Overall | 14 of 43 |
| Sector (Consumer Products) | 1 of 2 |
| Type (Add-on Acquisition) | 12 of 31 |
| Country (Denmark) | 1 of 1 |
| Year (2011) | 1 of 5 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2010-10-06 |
FoldRx Pharmaceuticals
Cambridge, Massachusetts, United States FoldRx Pharmaceuticals is a development and discovery company focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding and aggregation (amyloidosis). The Company's lead product, FX-4006, has begun a Phase II/III study in familial amyloid polyneuropathy. FoldRx Pharmaceuticals was founded in 2003 and is based in Cambridge, Massachusetts. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-03-01 |
King Pharmaceuticals
Bristol, Tennessee, United States King Pharmaceuticals LLC is a vertically integrated branded pharmaceutical company. King seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company's focus in specialty-driven markets, particularly neuroscience and hospital. King's wholly owned subsidiary, Alpharma, LLC, is also a leader in the development, registration, manufacture and marketing of pharmaceutical products for food producing animals. |
Buy | $3.6B |
| Category | Private Equity Firm |
|---|---|
| Founded | 2003 |
| PE ASSETS | 8.3B EUR |
| Size | Mega |
| Type | Sector Agnostic |
Altor Equity Partners is a private equity firm that looks to principally invest in medium-sized Nordic based companies across a broad range of industries. Altor typically seeks control positions when investing. Prospective companies generally have revenues of €50 to €500 million. Broad areas of interest include healthcare services, electronics, technology, financial services, business services, niche manufacturing, capital equipment, software, marine, consumer products, and communications. Altor Equity Partners was formed in 2003 and is based in Stockholm, Sweden.
| DEAL STATS | # |
|---|---|
| Overall | 8 of 41 |
| Sector (Consumer Products) | 1 of 1 |
| Type (Add-on Acquisition) | 6 of 23 |
| Country (Denmark) | 2 of 5 |
| Year (2011) | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-01-13 |
Aalborg Industries A/S
Aalborg, Denmark Aalborg Industries A/S is a supplier of boilers and ancillary installations for use in the engine rooms of large vessels and, to a lesser extent, boilers for industrial enterprises. |
Sell | kr5.0B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-03-14 |
Norsk Gjenvinning Norge AS
Oslo, Norway Norsk Gjenvinning Norge AS is a waste management company that provides services for all types of waste and operates along the whole value chain from collection through processing/recycling to selected downstream solutions. Norsk Gjenvinning was established in 1926 and is based in Oslo, Norway. |
Buy | - |
